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Non-competitive nature
• The ZAPI project is not focused on specific commercial
products.
• The ZAPI project aims to design new manufacturing
large scale capability processes for neutralizing
reagents and vaccines against zoonotic diseases.
• These new R&D and manufacturing processes should
be usable both for animal and human health needs

1st One Health IMI project
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The need to anticipate the future…
and preparedness activities

• It is always better to anticipate the risks..
• Major bio-threats are known (OIE list + (new
arthropod-borne diseases) + WHO initiatives…
• However, experience and recent history show
that some events are unpredictable…. And we
actually face the “unexpected” more and more.
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Global needs for new vaccines

• VACCINE PRODUCT « BY DESIGN »:
– Selection of protective immunogens
– Adjuvants, Immuno-modulators
– Delivery systems
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Global needs for new vaccines

• TECHNOLOGIES
– Many advantages to use recombinant technologies
as solutions for industrial bottlenecks:
• No handling of pathogens
• Large manufacturing capacity
• Less biological variability for the final product
• Easier QC testing for batch release
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Challenges for delivering
emergency vaccines
Technical constraints….
• Timelines (very short by definition = a few months…)
• Manufacturing capacity (with secured supply chains for
raw materials = source of many bottlenecks)

• Reliable processes / fully in vitro QC tools
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Challenges for delivering
emergency vaccines
Technical constraints (2)….
• Contained ABSL-3, ABSL-3+, ABSL-4 animal facilities for
testing vaccines …
• Stockpiling storage:
– Vaccine stability, facilities for vaccine storage  will drive the
selection of technical solutions

• If “immediate use” (implies efficient “surge capacity”):
– No need for long term stability (and for stockpiling ?)
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Challenges for delivering
emergency vaccines
Technical constraints (3)….
• Manufacturing capacities (with secured supply chains
for raw materials) (“capacity” can be a very complex
figure):
Minimum number of doses
Dose of antigen (linked to adjuvant, delivery route)
Key equipment for the process
Manufacturing average cycle time (reliability of process,
batch release success rate…)
– Stability (shelf life)
–
–
–
–

9

“New thinking” as part of
the preparedness
• Need to work with an “Industrial mindset” rather
than a “scientific mindset”. At the end of the day,

one delivers a product, not an experimental
vaccine…

• Better preparedness if vaccine solutions are based
on the “re-use” of existing (proven) manufacturing
technologies.
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“New thinking” as part of
the preparedness
• Viruses are perceived today as technically
achievable for this objective.
• 3 viral models are used in the ZAPI project:
– Rift Valley Fever Virus
– Schmallenberg Virus
– MERS-CoV

• Key progress in bioinformatics and new expression
systems enable now the implementation of
efficient subunit vaccine solutions
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Conclusions (1)
• For « expected events », the best approach is to

stockpile (« no delay » between identification and
implementation of field vaccination)
• However, this is associated with costs, technical
issues, and uncertainties…

• For « unexpected events », all timelines become
highly critical:
• Identification of pathogen / immunogen is key
• « Quality by Design » of the optimal vaccine for
« instant » manufacturing capacities
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Conclusions (2)
Necessity to innovate for designing subunit vaccines fit to
robust and « high yield » expression systems /
processes:
• Effectively achieving delivery of a product with
existing GMP facilities
• Ensuring surge manufacturing capacity

Timelines are critical for well-adapted responses:
• Select solutions enabling a short cycle time for
production:
• Rapid antigen production with high « volumetric
yields »
• Fast Quality Control (in vitro) for batch release
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Conclusions (3)
We are in a global « One World / One Health »
• Anyone (domestic animals, people) can or will be
exposed to new (re-)emerging diseases.
• The « reduction to effective field use » is too slow if
we follow the « old ways ».

It is time for a change and for action :
• Need to « act » the preparedness through large
collaborations
• Demonstration of the key industrial steps through
prototype projects such as ZAPI
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20 Partners in ZAPI consortium
EFPIA partners :

• Merial
• Boehringer Ingelheim Animal Health
• AstraZeneca / Medimmune

Public consortium partners:

SMEs

EFPIA coordinator
EFPIA partner
EFPIA partner

Erasmus Medical Center NL
CVI Lelystad NL
Utrecht University NL
Leyden University NL
FLI Riems DE
Institut Pasteur FR
IABS-EU FR / BE

Univ. Klin. Bonn DE
Viroclinics Biosciences NL
CSIC Madrid SP
IRTA-CReSA SP
TiHo Hannover DE
Aix-Marseille Univ. FR

Dyadic NDL Wageningen NL
Harbour Antibodies Rotterdam NL

Artemis NL
Finovatis FR
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